Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
Jacob Handlos Grauslund, Morten Orebo Holmström, Nicolai Grønne Jørgensen, Uffe Klausen, Stine Emilie Weis-Banke, Daniel El Fassi, Claudia Schöllkopf, Mette Borg Clausen, Lise Mette Rahbek Gjerdrum, Marie Fredslund Breinholt, Julie Westerlin Kjeldsen, Morten Hansen, Steffen Koschmieder, Nicolas Chatain, Guy Wayne Novotny, Jesper Petersen, Lasse Kjær, Vibe Skov, Özcan Met, Inge Marie Svane, Hans Carl Hasselbalch, Mads Hald Andersen
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2021.
All research outputs
#8,419,560
of 26,604,138 outputs
Outputs from Frontiers in oncology
#3,134
of 23,356 outputs
Outputs of similar age
#176,798
of 457,148 outputs
Outputs of similar age from Frontiers in oncology
#171
of 953 outputs
Altmetric has tracked 26,604,138 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 23,356 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 457,148 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 953 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.
